Phages themselves are relatively stable compared to many biologics, but transporting them internationally for clinical or aquaculture use raises serious hurdles:
Regulatory and safety barriers: Importing GMP phages from Europe or North America into Africa is a lengthy, uncertain process, and in many cases, they may not be permitted for direct therapeutic use. These have not been explored, but I can imagine how difficult it will be to get phage therapy across borders.
Customization to local pathogens: Phages are highly strain-specific. Local production allows us to isolate, adapt, and manufacture phages that actually match the pathogens circulating in our hospitals and farms.
Cost and logistics: Even if imports were possible, shipping live phage preparations under controlled conditions is expensive and delays treatment. In aquaculture, farmers need solutions within days, not months.
Sustainability and equity: Relying entirely on foreign production deepens Africa’s dependency on external suppliers. A local GMP facility builds capacity, jobs, and resilience within the region most affected by AMR.
So while global transport of phages is feasible, without local GMP capacity, Africa will remain locked out of real-world therapeutic use, which is why this facility is the critical missing link.
Thanks for sharing, this sounds very interesting.
Are the products hard to transport? It makes sense there would be a lot of need in Africa, but I am wondering why the production has to be local.
Thank you for this thoughtful question.
Phages themselves are relatively stable compared to many biologics, but transporting them internationally for clinical or aquaculture use raises serious hurdles:
Regulatory and safety barriers: Importing GMP phages from Europe or North America into Africa is a lengthy, uncertain process, and in many cases, they may not be permitted for direct therapeutic use. These have not been explored, but I can imagine how difficult it will be to get phage therapy across borders.
Customization to local pathogens: Phages are highly strain-specific. Local production allows us to isolate, adapt, and manufacture phages that actually match the pathogens circulating in our hospitals and farms.
Cost and logistics: Even if imports were possible, shipping live phage preparations under controlled conditions is expensive and delays treatment. In aquaculture, farmers need solutions within days, not months.
Sustainability and equity: Relying entirely on foreign production deepens Africa’s dependency on external suppliers. A local GMP facility builds capacity, jobs, and resilience within the region most affected by AMR.
So while global transport of phages is feasible, without local GMP capacity, Africa will remain locked out of real-world therapeutic use, which is why this facility is the critical missing link.